South Africa Breast Cancer Therapeutics Market Report 2022 to 2030

South Africa Breast Cancer Therapeutics Market Analysis

$ 3999

The South Africa breast cancer therapeutics market size was valued at $118 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of xx% from 2022 to 2030 and will reach $xx Mn in 2030. Increasing awareness initiatives for breast cancer by the government and new drug developments for the treatment of breast cancer are driving the South Africa breast cancer therapeutics market. The market is segmented by therapy, by cancer type, and by distribution channel. Some of the major market players in the South Africa breast cancer therapeutics market are Dis-Chem Pharmacies, AstraZeneca, and Eisai.

ID: IN10ZAPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: South Africa AUTHOR: Parul Choudhary

Buy Now

South Africa Breast Cancer Therapeutics Market Executive Analysis

The South Africa breast cancer therapeutics market size is at around $118 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. South Africa spends $15.03 Bn on health, an increase over the updated forecast of $14.87 Bn in 2021. This includes $6.12 Bn for district health services, $2.98 Bn for other health services, $2.56 Bn for services at the central hospital, $2.21 Bn for services at the provincial hospital, and $0.56 Bn for facilities management and upkeep. As expenditures for COVID-19 wind down, the health baseline would account for $44.36 Bn (or 13.8%) of the government of South Africa's consolidated total spending in the medium term, a slight decline from $15.03 Bn in 2022-23 to $14.95 Bn in 2024-25.

Breast cancer incidence in 2012 was estimated by the International Agency for Cancer Research (IARC) to range from 27 per 100 000 women in central Africa to 39 per 100 000 women in southern Africa. Although breast cancer seems to occur less frequently in Sub-Saharan Africa (SSA), overall survival rates are low there, with significant mortality rates noted in several contexts. In addition to other competing public health concerns, inadequate funding, and poor healthcare infrastructure have all been linked to the low survival of breast cancer patients in SSA. Neoadjuvant chemotherapy (NAC) vs. adjuvant chemotherapy (AC) in patients with advanced and early-stage breast cancer (ESBC) has advanced significantly, with several ground-breaking studies demonstrating definite survival advantages for newer regimens after radiation, lumpectomy, or mastectomy. Therapy is still very difficult because anthracyclines and taxanes do not enhance the prognosis of the disease. Increased advancements in the application of particular biomarkers have yielded noteworthy outcomes. In addition, different radiation approaches are employed to treat women with various stages of tumor development in South Africa.

Market Dynamics

Market Growth Drivers

Increased pharmaceutical drug development, government awareness-raising initiatives, rapid acceptance of new screening measures, and rising healthcare spending for the treatment of breast cancer are major market drivers for the South Africa breast cancer therapeutics market.

Market Restraints

Considering the rising cost of the advanced medicines used to treat breast cancer. Chemotherapy is the most expensive therapy due to the rising cost of the pharmaceuticals used in breast cancer treatment. Because of the higher cost, not everyone can opt for chemotherapy, which could lead to a drop in the South Africa breast cancer therapeutics market.

Competitive Landscape

Key Players

Aspen (ZAF)
Adcock Ingram (ZAF)
Nkunzi Pharmaceuticals (ZAF)
Dis-Chem Pharmacies (ZAF)
AstraZeneca
Eisai
Eli Lilly
Roche

Healthcare Policies and Regulatory Landscape

NHI (National Health Insurance) is a system for financing healthcare that aims to pool resources to give all South Africans, regardless of socioeconomic level, access to high-quality, reasonably priced personal health services based on their individual health requirements. All South Africans will have universal health coverage provided by NHI. This explicitly refers to insurance for one's financial stability. It will establish a single public health fund with enough funds to adequately plan for and efficiently address all population health requirements. The NHI offers a comprehensive range of services related to breast cancer detection, treatment, and management, including mammography, biopsies, and surgery. Depending on the specific policy and the degree of coverage selected by the policyholder, private insurance firms may give different levels of coverage and reimbursement. Some private health insurance plans might not fully cover the price of all breast cancer treatments, leaving the policyholder with some out-of-pocket expenses.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.